In today’s recent session, 1.61 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have been traded, and its beta is 0.90. Most recently the company’s share price was $7.44, and it changed around $0.09 or 1.24% from the last close, which brings the market valuation of the company to $1.61B. RXRX at last check was trading at a discount to its 52-week high of $16.75, offering almost -125.13% off that amount. The share price’s 52-week low was $4.54, which indicates that the recent value has risen by an impressive 38.98% since then. We note from Recursion Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 6.30 million.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX has been showing a green trend so far today with a performance of 1.24% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently down -24.54% year-to-date, but still down -4.48% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -30.13% down in the 30-day period.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Recursion Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 22.99 percent over the past six months and at a -3.16% annual growth rate that is well below the industry average of 10.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -23.50% in revenue this quarter, and will report a decrease of -10.50% in the next quarter. The year-over-year growth rate is expected to be 26.00%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $12.65 million in revenue for the current quarter. 6 analysts expect Recursion Pharmaceuticals Inc to make $13.17 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $12.13 million and $11.02 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 4.30%. Forecasts for the next quarter put sales growth at 19.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.41%. Recursion Pharmaceuticals Inc earnings are expected to increase by -9.14% in 2024, but the outlook is positive 12.00% per year for the next five years.
